首页> 外文期刊>Genetic Testing >Association Between Vascular Endothelial Growth Factor+936 Genotype and Acute Respiratory Distress Syndrome in a Chinese Population
【24h】

Association Between Vascular Endothelial Growth Factor+936 Genotype and Acute Respiratory Distress Syndrome in a Chinese Population

机译:血管内皮生长因子+ 936基因型与中国人群急性呼吸窘迫综合征的关系。

获取原文
获取原文并翻译 | 示例
       

摘要

Acute respiratory distress syndrome (ARDS) is an often fatal condition for which a genetic predisposition is postulated, although no specific genes have been identified to date. Vascular endothelial growth factor (VEGF) is postulated to have a role in ARDS. The objective of this study is to explore whether the VEGF+936 genotype is associated with ARDS in a Chinese population. A hospital-based case-control study was conducted in 170 cases of ARDS and 170 controls. Polymerase chain reaction-restriction fragment length polymorphism analysis was performed to detect the VEGF+936 genotype. Patients with ARDS had a significantly higher frequency of TT genotype (odds ratio=3.85,95% confidence interval = 1.05,14.06; p = 0.04) than controls. The TT genotype was significantly associated with increased mortality from ARDS (odds ratio=5.72, 95% confidence interval = 1.20, 27.33; p=0.03). This study suggests that the VEGF+936 TT genotype is a risk factor and may contribute to the prognosis of ARDS in the Chinese population. Further studies are needed to elucidate the mechanism of this association as well as to study its effects on larger populations.
机译:急性呼吸窘迫综合症(ARDS)是一种致命的疾病,假定有遗传易感性,尽管迄今为止尚未发现具体的基因。假设血管内皮生长因子(VEGF)在ARDS中起作用。这项研究的目的是探讨在中国人群中VEGF + 936基因型是否与ARDS相关。一项基于医院的病例对照研究在170例ARDS和170例对照中进行。进行聚合酶链反应-限制性片段长度多态性分析以检测VEGF + 936基因型。 ARDS患者的TT基因型频率显着高于对照组(比值= 3.85,95%置信区间= 1.05,14.06; p = 0.04)。 TT基因型与ARDS死亡率增加显着相关(赔率= 5.72,95%置信区间= 1.20,27.33; p = 0.03)。这项研究表明,VEGF + 936 TT基因型是一个危险因素,可能有助于中国人群ARDS的预后。需要进一步研究以阐明这种关联的机制,并研究其对更大人群的影响。

著录项

  • 来源
    《Genetic Testing》 |2011年第10期|p.737-740|共4页
  • 作者单位

    Department of Anesthesiology ,Tianjin Medical University Cancer Institute and Hospital, Tianjin, China,National Key Laboratory of Breast Cancer Prevention and Treatment, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China,Department of Anesthesiology Tianjin Medical University Cancer Institute and Hospital Hexi District Tianjin 300060 China;

    Emergence Department of Tianjin First Center Hospital, Tianjin, China;

    Department of Anesthesiology ,Tianjin Medical University Cancer Institute and Hospital, Tianjin, China;

    Emergence Department of Tianjin First Center Hospital, Tianjin, China;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 13:19:27

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号